Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating bronchial asthma and application thereof

A technology for bronchial asthma and a composition, which is applied in the field of medicine to achieve the effects of improving lung function, reducing dosage and reducing airway responsiveness

Inactive Publication Date: 2014-08-20
NANTONG QIWU AGRI PROD CO LTD
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, by searching the existing technologies at home and abroad, it is found that in the treatment of bronchial asthma, there is no therapeutic drug with morroniside or the combination of morroniside and dexamethasone acetate as the main active ingredient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating bronchial asthma and application thereof
  • Pharmaceutical composition for treating bronchial asthma and application thereof
  • Pharmaceutical composition for treating bronchial asthma and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The following are specific examples of the present invention, and further describe the technical solution of the present invention, but the protection scope of the present invention is not limited to these examples. All changes or equivalent substitutions that do not depart from the concept of the present invention are included in the protection scope of the present invention.

[0018] 60 clean SD rats, half male and half male, body weight 180-220g. All rats were randomly divided into normal control group, model control group, dexamethasone group, morroniside group and compound group, 12 in each group. Animal models of bronchial asthma were prepared by ovalbumin (OVA) sensitization. Except for the normal control group, animals in the other four groups were treated with OVA 10 mg, A1(OH) 3 Dry powder 100mg normal saline suspension 1mL intraperitoneal injection for sensitization, repeat sensitization once on the 8th day, start ultrasonic atomization 1% 0VA for excitatio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating bronchial asthma and application thereof. The pharmaceutical composition contains morroniside and dexamethasone acetate in a weight ratio of 60-360 to 1. The pharmaceutical composition has the important advantages that morroniside and dexamethasone acetate are coordinated to relieve asthma, improve the lung function of a rat with bronchial asthma, as well as reduce airway responsiveness, so as to reach the purpose of treating bronchial asthma.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating bronchial asthma and its application. Background technique [0002] Bronchial asthma (referred to as asthma) is a chronic airway inflammatory disease characterized by the participation of cells such as eosinophils, T lymphocytes, mast cells, and macrophages and a series of cytokines, which seriously threatens public health. Its main pathological features are acute and chronic airway inflammation, smooth muscle dysfunction and airway remodeling. According to WHO estimates, 15 million people lose their working ability due to asthma every year, accounting for 1% of the global disease burden, and the number of people who die from asthma every year worldwide It has reached 250,000 people, and patients and the society have paid a huge amount of money to control asthma, which has brought a great economic burden to the society. There...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P11/06A61K31/573
CPCA61K31/573A61K31/7048A61K2300/00
Inventor 谷建海
Owner NANTONG QIWU AGRI PROD CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com